Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Salanersen · BIIB115

Oligonucleotide (Antisense oligonucleotide) · developed by BIOGEN

Phase 3 Most advanced trial

BIIB Developer

1 Registered trials

What is Salanersen?

Salanersen (BIIB115) is an antisense oligonucleotide administered intrathecally, studied in spinal muscular atrophy.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: BIIB115
Drug type: Oligonucleotide (Antisense oligonucleotide)
Therapy area: Neurology
Developer: BIOGEN (BIIB)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: PTC9GTD4E7

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07444450	Phase 3	Muscular Atrophy, Spinal	Recruiting	BIIB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Muscular Atrophy, Spinal

More from BIOGEN

Dimethyl Fumarate FDA approved Diroximel Fumarate FDA approved Interferon Beta-1A FDA approved Natalizumab FDA approved Nusinersen FDA approved Omaveloxolone FDA approved Tofersen FDA approved Zuranolone FDA approved BIIB115 Phase 1 BIIB122 Phase 3 BIIB144 Phase 1 BIIB147 Phase 1/2

Sources

ClinicalTrials.gov NCT07444450

Updated Oct 3, 2026. Something wrong or missing? Report it on the BIIB page.

Follow BIIB, the company behind Salanersen

See BIIB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BIIB catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z